FDA approves Novo Nordisk drug to treat rare condition
On Monday, the US Food and Drug Administration (FDA) approved Novo Nordisk’s drug Rivfloza for the treatment of primary hyperoxaluria type 1.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA to review Novo Nordisk drug for rare metabolic disease
For subscribers
Huge acquisition scores Novo Nordisk an FDA-ready treatment
For subscribers